Dr. Purushottam Lamichhane is an assistant professor of microbiology/immunology at LECOM School of Dental Medicine. Dr. Lamichhane completed his bachelor's degree in biology, with minors in physics and mathematics, at Buena Vista University in Storm Lake, IA. He received his Ph.D. in immunology from the Mayo Clinic in Rochester, MN. He continued his research as a postdoctoral fellow at University of Miami Miller School of Medicine. Dr. Lamichhane’s research is focused on understanding the innate and adaptive immune resistance in the tumor microenvironment. Specifically, his work has aimed to elucidate the mechanism of regulation of immune checkpoint molecules’ (PD-1/PD-L1, CTLA-4) expression and therapy induced adaptive and inherent innate resistance to blockade of these checkpoint molecules. He is also interested in understanding the mechanisms of immune dysfunctions that contribute to periodontal diseases.
1. Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy? Lamichhane, P.; Amin, N.P.; Agarwal, M.; Lamichhane, N. Medicines 2018, 5, 114.
2. Oral Microbiome and Response to Immunotherapy: Is It Time To Pay Attention? Lamichhane P. On J Dent & Oral Health. 1(1): 2018. OJDOH.MS.ID.000501.
3. Tobacco carcinogen-induced production of GM-CSF activates CREB to promote pancreatic cancer. Srinivasan S, Totigeri T, Shi C, Castellanos J, Lamichhane P, Dosch AR, Kashikar N, Honnenahally K, Ban Y, Merchant NB, Vansaun M, and Nagathihalli N. Cancer Res. 2018.
4. Inverse correlation of STAT3 and MEK signaling mediates resistance to RAS pathway inhibition in pancreatic cancer. Nagathihalli N, Castellanos J, Lamichhane P, Messaggio F, Shi C, Dai X, Rai P, Chen X, VanSaun M, and Merchant N. Cancer Res. 2018.
5. Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer. Totigeri T*, Srinivasan S*, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA, Joshi C, Rangappa S, Castellanos J, Vermula PK, Chen X, Kwon D, Kashikar N, VanSaun M, Merchant N, and Nagathihalli N. Mol Cancer Ther. 2018.
6. IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Lamichhane P, Karyampudli L, Shreeder B, and Knutson KL. Cancer Res. 2017 Dec 1;77(23):6667-6678.
7. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Lavakumar Karyampudi*, Purushottam Lamichhane*, James Krempski, Kimberly R. Kalli, Marshall D. Behrens, Doris M. Vargas, Lynn C Hartmann, Jo Marie T Janco, Haidong Dong, Karen E Hedin, Allan B. Dietz, Ellen L. Goode, and Keith L. Knutson. Cancer Res. 2016 Jan 15;76(2):239-50 . *LK and PL are equal first authors.
8. Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. Jo Marie Tran Janco, Purushottam Lamichhane, Lavakumar Karyampudi, and Keith L. Knutson. J Immunol. 2015 April 1.194:2985-2991.
9. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Cancer Res. 2014 Jun 1;74(11):2974-85.